Company Filing History:
1 out of 832,880 Years Active: 2019
Title: Innovations in Alzheimer's Treatment by Hsin-Hua Li
Introduction
Hsin-Hua Li is an innovative inventor based in Taichung, Taiwan. He has made significant contributions to the field of medicine, particularly in the treatment of Alzheimer's disease. His work focuses on the use of microRNAs as therapeutic agents, showcasing the potential of genetic engineering in addressing complex health issues.
Latest Patents
Hsin-Hua Li holds a patent for a composition and method of using miR-302 precursors as drugs for treating Alzheimer's disease. This invention relates to the use of recombinant microRNAs and their hairpin-like precursors as therapeutic drugs. Specifically, it involves the use of man-made miR-302 precursors for therapy in humans. The invention also includes a novel method for expressing pre-miRNAs in prokaryotes, which can lead to advancements in regenerative medicine for various aging-related degenerative diseases.
Career Highlights
Throughout his career, Hsin-Hua Li has focused on the intersection of genetics and medicine. His innovative approach to using miR-302 precursors has opened new avenues for research and treatment in neurodegenerative diseases. His work is a testament to the potential of biotechnology in improving human health.
Collaborations
Hsin-Hua Li has collaborated with notable colleagues, including Chih-Li Lin and Shi-Lung Lin. These partnerships have enhanced the research and development of his innovative therapies, contributing to the advancement of medical science.
Conclusion
Hsin-Hua Li's contributions to the field of Alzheimer's treatment through his innovative use of miR-302 precursors highlight the importance of genetic research in medicine. His work not only addresses Alzheimer's disease but also paves the way for future advancements in treating other degenerative conditions.